Literature DB >> 16511930

Treatment of pediatric localized scleroderma with methotrexate.

Pamela G Fitch1, Patricia Rettig, Jon M Burnham, Terri H Finkel, Albert C Yan, Evren Akin, Randy Q Cron.   

Abstract

OBJECTIVE: To analyze the effectiveness of methotrexate (MTX) for the therapy of pediatric localized scleroderma (LS).
METHODS: A retrospective chart review was performed for 17 pediatric patients with LS who failed topical therapy and were subsequently treated with MTX (12.5-25 mg weekly) with or without oral corticosteroids. A structured followup telephone call to the families was used to assess patient satisfaction.
RESULTS: Skin findings improved in 16 of 17 patients with a median time to improvement of 2.25 and 2.0 months for MTX alone or in combination with corticosteroids. Only one patient had active lesions at the most recent followup visit. Fifteen of 17 families reported improvement in their child's lesions after beginning MTX. Twelve of 17 patients were treated with MTX and oral corticosteroids. There were no major adverse events.
CONCLUSION: MTX appears to be a safe and effective therapy for pediatric LS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16511930

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

1.  Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study.

Authors:  Kathryn S Torok; Thaschawee Arkachaisri
Journal:  J Rheumatol       Date:  2012-01-15       Impact factor: 4.666

2.  Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma.

Authors:  Suzanne C Li; Kathryn S Torok; Elena Pope; Fatma Dedeoglu; Sandy Hong; Heidi T Jacobe; C Egla Rabinovich; Ronald M Laxer; Gloria C Higgins; Polly J Ferguson; Andrew Lasky; Kevin Baszis; Mara Becker; Sarah Campillo; Victoria Cartwright; Michael Cidon; Christi J Inman; Rita Jerath; Kathleen M O'Neil; Sheetal Vora; Andrew Zeft; Carol A Wallace; Norman T Ilowite; Robert C Fuhlbrigge
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-08       Impact factor: 4.794

3.  Characteristics of coexisting localized scleroderma and inflammatory arthritis.

Authors:  Daniel Reiff; Courtney B Crayne; Melissa L Mannion; Randy Q Cron
Journal:  Eur J Rheumatol       Date:  2019-12-03

4.  Longstanding epileptic encephalopathy and linear localized scleroderma: two distinct pathologic processes in an adolescent.

Authors:  Donato Rigante; Domenica Battaglia; Ilaria Contaldo; Ilaria La Torraca; Laura Avallone; Stefania Gaspari; Giulia Bersani; Achille Stabile
Journal:  Rheumatol Int       Date:  2008-02-16       Impact factor: 2.631

Review 5.  Pediatric scleroderma: systemic or localized forms.

Authors:  Kathryn S Torok
Journal:  Pediatr Clin North Am       Date:  2012-04-06       Impact factor: 3.278

6.  Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea.

Authors:  Megan Arthur; Nicole M Fett; Emile Latour; Heidi Jacobe; Elaine Kunzler; Stephanie Florez-Pollack; Jacob Houser; Shivani Sharma; Smriti Prasad; Alisa Femia; Marleigh J Stern; Lisa K Pappas-Taffer; Rebecca Gaffney; Anthony P Fernandez; Daniel Knabel; Adela Rambi Cardones; Nicole Leung; Anne Laumann; Jeong Min Yu; Jeffrey Zhao; Ruth Ann Vleugels; Elizabeth Tkachenko; Kelly Lo
Journal:  JAMA Dermatol       Date:  2020-05-01       Impact factor: 10.282

Review 7.  Localized scleroderma: clinical spectrum and therapeutic update.

Authors:  Mariana Figueiroa Careta; Ricardo Romiti
Journal:  An Bras Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.896

Review 8.  Morphea and Eosinophilic Fasciitis: An Update.

Authors:  Jorre S Mertens; Marieke M B Seyger; Rogier M Thurlings; Timothy R D J Radstake; Elke M G J de Jong
Journal:  Am J Clin Dermatol       Date:  2017-08       Impact factor: 7.403

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.